Amgen ends partnership with TScan Therapeutics as Amylyx announces $350 million offering
Amgen announced it is terminating its collaboration with TScan Therapeutics, a Waltham, Massachusetts company focused on T‑cell therapies.
The decision ends a partnership that had been aimed at developing next‑generation immunotherapies, though the statement did not disclose financial terms or reasons for the split.
In the same briefing, Amylyx disclosed a $350 million financing package to support its pipeline, highlighting continued capital‑raising activity in the sector.
The news brief also listed updates from BioArctic, Enveda, Georgiamune, Kynexis, Tolerance Bio and Network Bio, but no further details were provided.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Amgen cans its TScan partnership; Amylyx reveals $350M offering”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that